Cargando…
Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site
Abiraterone acetate is a first-line therapy for castration-resistant prostate cancer. This prodrug is deacetylated in vivo to abiraterone, which is a potent and specific inhibitor of cytochrome P450 17A1 (CYP17A1). CYP17A1 performs two sequential steps that are required for the biosynthesis of andro...
Autores principales: | Petrunak, Elyse M., Bart, Aaron G., Peng, Hwei-Ming, Auchus, Richard J., Scott, Emily E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023946/ https://www.ncbi.nlm.nih.gov/pubmed/36773804 http://dx.doi.org/10.1016/j.jbc.2023.102999 |
Ejemplares similares
-
Epoxidation Activities of Human Cytochromes P450c17
and P450c21
por: Yoshimoto, Francis K., et al.
Publicado: (2014) -
Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors
por: Bonomo, Silvia, et al.
Publicado: (2016) -
Substrate binding induces structural changes in cytochrome P450cam
por: Sakurai, Keisuke, et al.
Publicado: (2009) -
CYTOCHROME P450 17A1 STRUCTURES WITH PROSTATE CANCER DRUGS ABIRATERONE AND TOK-001
por: DeVore, Natasha M., et al.
Publicado: (2012) -
Interaction Modes of Microsomal Cytochrome P450s with Its Reductase and the Role of Substrate Binding
por: Esteves, Francisco, et al.
Publicado: (2020)